Richard Nathan

2.2k total citations · 1 hit paper
7 papers, 666 citations indexed

About

Richard Nathan is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Richard Nathan has authored 7 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 4 papers in Epidemiology and 1 paper in Surgery. Recurrent topics in Richard Nathan's work include Clostridium difficile and Clostridium perfringens research (5 papers), Viral gastroenteritis research and epidemiology (2 papers) and Microscopic Colitis (2 papers). Richard Nathan is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (5 papers), Viral gastroenteritis research and epidemiology (2 papers) and Microscopic Colitis (2 papers). Richard Nathan collaborates with scholars based in United States, Germany and Canada. Richard Nathan's co-authors include Richard Pollak, Victoria Landolfi, Andrew J. Dunning, Avi Collins, Nadia Tornieporth, John Earl, John J. Treanor, Daniel Kirby, Murray Kimmel and Carlos A. DiazGranados and has published in prestigious journals such as New England Journal of Medicine, Vaccine and Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy.

In The Last Decade

Richard Nathan

7 papers receiving 653 citations

Hit Papers

Efficacy of High-Dose versus Standard-Dose Influenza Vacc... 2014 2026 2018 2022 2014 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Nathan United States 6 526 239 119 113 54 7 666
Murray Kimmel United States 4 461 0.9× 147 0.6× 117 1.0× 111 1.0× 63 1.2× 5 604
Avi Collins United States 3 457 0.9× 137 0.6× 113 0.9× 113 1.0× 46 0.9× 4 568
Kwok‐Hung Chan Hong Kong 15 596 1.1× 193 0.8× 100 0.8× 68 0.6× 43 0.8× 22 651
Ahmad Razmpour United States 12 869 1.7× 205 0.9× 151 1.3× 107 0.9× 44 0.8× 15 956
Victoria Landolfi United States 14 956 1.8× 324 1.4× 280 2.4× 223 2.0× 116 2.1× 20 1.2k
Monika Redlberger‐Fritz Austria 15 480 0.9× 245 1.0× 84 0.7× 65 0.6× 59 1.1× 44 655
Wendy Sessions United States 11 662 1.3× 313 1.3× 119 1.0× 70 0.6× 105 1.9× 17 826
Julie Cordova United States 13 731 1.4× 255 1.1× 135 1.1× 119 1.1× 27 0.5× 13 839
Daixi Jiang China 14 282 0.5× 243 1.0× 30 0.3× 60 0.5× 37 0.7× 31 523
Frank Kowalzik Germany 9 237 0.5× 163 0.7× 61 0.5× 65 0.6× 99 1.8× 22 492

Countries citing papers authored by Richard Nathan

Since Specialization
Citations

This map shows the geographic impact of Richard Nathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Nathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Nathan more than expected).

Fields of papers citing papers by Richard Nathan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Nathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Nathan. The network helps show where Richard Nathan may publish in the future.

Co-authorship network of co-authors of Richard Nathan

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Nathan. A scholar is included among the top collaborators of Richard Nathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Nathan. Richard Nathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
2.
Cornely, Oliver A., Kathleen M. Mullane, Thomas Birch, et al.. (2020). Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer. Open Forum Infectious Diseases. 7(2). ofaa038–ofaa038. 9 indexed citations
3.
Ford, Christopher B., Barbara McGovern, Darrell S. Pardi, et al.. (2019). 1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI). Open Forum Infectious Diseases. 6(Supplement_2). S547–S548. 9 indexed citations
4.
Bruyn, Guy de, David Workman, Richard Pollak, et al.. (2016). Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine. 34(19). 2170–2178. 76 indexed citations
6.
DiazGranados, Carlos A., Andrew J. Dunning, Murray Kimmel, et al.. (2014). Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults. New England Journal of Medicine. 371(7). 635–645. 549 indexed citations breakdown →
7.
Buitrago, Martha, et al.. (2009). Extremely Low Excretion of Daptomycin into Breast Milk of a Nursing Mother with Methicillin‐Resistant Staphylococcus aureus Pelvic Inflammatory Disease. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 29(3). 347–351. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026